AI Summary Dapagliflozin (Farxiga/Forxiga) is a prescription SGLT2 inhibitor that may be considered for eligible patients with MASLD or MASH to help manage underlying metabolic, cardiovascular, and kidney risk factors.
Medically reviewed.
Dapagliflozin (Farxiga/Forxiga) is a prescription sodium-glucose cotransporter 2 (SGLT2) inhibitor approved to improve glycemic control in adults with type 2 diabetes. It is also approved to reduce the risk of hospitalization for heart failure in adults with and without type 2 diabetes, and to reduce the risk of sustained eGFR decline, end-stage kidney disease, cardiovascular death, and heart failure hospitalization in adults with chronic kidney disease. Because obesity, insulin resistance, and type 2 diabetes are closely linked to MASLD and MASH, some healthcare providers may consider dapagliflozin for eligible patients to help manage these underlying metabolic risk factors, even though it is not FDA-approved specifically for liver disease. Treatment decisions should always be individualized and guided by a healthcare professional.
This page covers dapagliflozin's role in metabolic and MASLD/MASH management — how it works, who may be eligible, benefits, side effects, and monitoring. You can also connect with a liver specialist near you for personalized guidance on whether dapagliflozin fits your care plan.
Liver Health AI Assistant
Ask Aimy
Aimy answers from LiverDirectory’s reviewed health information — helping patients make sense of liver-health terms, prepare for specialist visits, and explore what to look up next.
ABOUT DAPAGLIFLOZIN TREATMENT
Dapagliflozin is a prescription medicine sold under the brand names Farxiga (United States) and Forxiga (Europe and other regions). It belongs to a class of medications called sodium-glucose cotransporter 2 (SGLT2) inhibitors, which work in the kidneys rather than the liver or pancreas.
Dapagliflozin is approved to improve glycemic control in adults with type 2 diabetes. It is also approved to reduce the risk of hospitalization for heart failure in adults with and without type 2 diabetes, and to reduce the risk of sustained eGFR decline, end-stage kidney disease, cardiovascular death, and heart failure hospitalization in adults with chronic kidney disease.
Because obesity, insulin resistance, and elevated blood sugar are closely linked to MASLD and MASH, some healthcare providers prescribe dapagliflozin to address these underlying metabolic risk factors, even though it is not a direct liver treatment.
It is typically used as part of a broader, personalised treatment plan that may include dietary changes, physical activity, and regular monitoring by your healthcare provider, such as Liver Function Tests (LFTs) or imaging.
WHO DAPAGLIFLOZIN MAY BE SUITABLE FOR
Eligibility for dapagliflozin depends on the medication's approved uses, your diagnosis, and your individual health needs. Dapagliflozin is approved for adults with type 2 diabetes who need additional glycemic control, and for adults with heart failure or chronic kidney disease who need a reduction in cardiovascular or renal risk. It may be considered for people who meet these criteria and who also have MASLD or MASH linked to metabolic risk factors such as obesity, insulin resistance, or elevated blood sugar.
Your medical history, current health status, liver condition, kidney function, and any other medications you take all factor into whether dapagliflozin is an appropriate option for you.
Because every patient's health profile is different, there is no one-size-fits-all answer to who should take dapagliflozin. Treatment decisions are individualized and should be made by a qualified healthcare professional after a full assessment of your liver condition, metabolic health, and treatment goals. Your doctor will weigh the potential benefits against any risks, including the need for adequate hydration, before determining whether dapagliflozin fits safely into your broader care plan.
ELIGIBILITY OVERVIEW
Dapagliflozin may be considered for adults with the following conditions, risk factors, or treatment goals:
Before recommending dapagliflozin, healthcare providers evaluate several factors to determine whether it is an appropriate option, including:
HOW DAPAGLIFLOZIN CAN HELP YOUR LIVER
Dapagliflozin inhibits sodium-glucose cotransporter 2 (SGLT2) in the kidney. This reduces how much glucose the kidneys reabsorb back into the blood and increases how much glucose is removed through urine, which lowers blood sugar levels independently of insulin.
This action targets metabolic drivers behind MASLD and MASH: elevated blood sugar, excess body weight, and cardiovascular and kidney risk. As blood glucose and body weight improve, some of the metabolic strain linked to fat buildup in the liver may ease as well.
For patients with MASLD or MASH and related metabolic conditions, these changes can support treatment goals such as better glycemic control, modest weight support, and reduced cardiovascular or kidney risk. Dapagliflozin is not used on its own — providers pair it with dietary changes, physical activity, and regular monitoring, such as Liver Function Tests (LFTs), to support these outcomes.
LIVER BENEFITS
Elevated blood sugar and insulin resistance are central metabolic pathways in MASLD and MASH. Dapagliflozin lowers blood glucose by increasing urinary glucose excretion, independent of insulin, supporting healthier blood sugar regulation.
Excess body weight contributes to fat buildup in the liver. Dapagliflozin may assist with modest weight management as part of a broader, personalized care plan that includes diet and physical activity.
Dapagliflozin reduces the risk of hospitalization for heart failure and supports renal function in eligible patients with chronic kidney disease. Because cardiovascular and kidney disease are common in people with MASLD and MASH, these effects address closely linked metabolic risks.
MASLD can progress to MASH, liver fibrosis, or cirrhosis over time. Improving blood sugar, weight, and cardiovascular or kidney risk factors may help lower some of the metabolic pressures linked to disease progression, although individual outcomes vary.
Dapagliflozin supports metabolic health by improving blood sugar control and offering cardiovascular and kidney benefits, which may help people with MASLD or MASH who also have these conditions. It should only be started and monitored under the guidance of a qualified healthcare professional.
TREATMENT PROCESS
Dapagliflozin is supplied as an oral tablet. Take it exactly as prescribed by your healthcare provider, and check with your pharmacist if you have any questions about your specific tablet strength.
The usual dose is 10 mg once daily. In some cases, treatment may be started at 5 mg once daily and increased to 10 mg once daily depending on indication, tolerability, and clinical response. Your healthcare provider determines the right dose for you.
Dapagliflozin is a once-daily oral tablet — it is not an injection or infusion. Take it with or without food at the same time each day, and maintain adequate hydration. Always use it exactly as your healthcare provider directs, and do not adjust your dose without medical guidance.
Dapagliflozin is generally used as a long-term therapy for type 2 diabetes, heart failure, or chronic kidney disease. Treatment is typically continued as long as clinical benefit is observed and the medication is well tolerated. Do not stop taking it without first talking to your healthcare provider.
Store dapagliflozin tablets at room temperature, away from moisture and heat.
Your healthcare provider will regularly monitor blood glucose levels, kidney function, hydration status, and overall treatment response. For people using dapagliflozin to support MASLD or MASH management, providers may also monitor liver health measures, such as Liver Function Tests (LFTs), alongside routine follow-up. Report any side effects or unusual symptoms to your healthcare provider.
BENEFITS AND SAFETY
Dapagliflozin (Farxiga/Forxiga) may support people with MASLD and MASH by targeting shared metabolic risk factors — elevated blood sugar, excess weight, and cardiovascular or kidney risk — that often accompany fatty liver disease. By lowering blood glucose independently of insulin and offering proven cardiovascular and kidney benefits, it may help improve the overall metabolic health picture for eligible patients, though it is not a direct treatment for liver fat or inflammation. The extent of these benefits varies from person to person, depending on liver condition, overall metabolic health, treatment plan, and how the body responds to therapy. Dapagliflozin is not a stand-alone liver treatment — it works best as part of a broader, personalised care plan that combines the medication with lifestyle changes, such as a liver-healthy diet and regular physical activity, along with ongoing monitoring like Liver Function Tests (LFTs) or imaging.
As with any medication, dapagliflozin may cause side effects, ranging from urinary and genital infections to dehydration. Your healthcare provider will assess whether dapagliflozin is a suitable option for you and will monitor your treatment response throughout therapy, adjusting the dose or overall care plan as needed to balance potential benefits against any risks.
BENEFITS
Dapagliflozin lowers blood glucose levels independently of insulin by increasing urinary glucose excretion, helping improve overall glycemic control in adults with type 2 diabetes.
Dapagliflozin may assist with weight management and reduction of excess body weight when combined with diet and exercise, which can help address a key driver of fat buildup in the liver.
Dapagliflozin reduces the risk of hospitalization for heart failure in adults with and without type 2 diabetes, offering a cardiovascular benefit that is especially relevant given the shared risk factors between MASLD/MASH and heart disease.
Dapagliflozin supports renal function and reduces the risk of sustained eGFR decline and end-stage kidney disease in eligible patients with chronic kidney disease.
These effects are often more noticeable when starting treatment or if fluid intake is low, and may improve over time. Your healthcare provider will discuss the potential benefits and risks before treatment and provide ongoing support, including hydration guidance, to ensure safe use.
SUPPORTING YOUR RESULTS
Lifestyle changes are an important part of a comprehensive treatment plan alongside dapagliflozin. Adjustments in nutrition, physical activity, hydration, and weight management may all play a role in supporting your results.
These habits can support how your body responds to treatment and may help improve outcomes over time.
Areas that may support treatment:
COMMON QUESTIONS
No. Dapagliflozin (Farxiga/Forxiga) is not approved as a direct treatment for MASLD or MASH. The FDA has approved it for type 2 diabetes, heart failure, and chronic kidney disease. Obesity, insulin resistance, and high blood sugar often accompany fatty liver disease, so some healthcare providers consider dapagliflozin for eligible patients as part of a broader metabolic care plan. It works best alongside a balanced diet, regular physical activity, and ongoing monitoring. Ask your healthcare provider whether it fits your goals.
Your provider may consider it to address the metabolic conditions that often come with MASLD and MASH. Dapagliflozin lowers blood sugar, may support modest weight management, and may reduce the risk of certain heart and kidney complications. Improving these factors may ease some of the metabolic strain linked to fat buildup in the liver, although results vary from person to person. Your provider will look at your liver condition, kidney function, medical history, and current medicines before deciding.
They work in different ways. Dapagliflozin is an SGLT2 inhibitor that works in the kidneys. It lowers blood sugar by increasing the amount of glucose removed in urine, and it is a once-daily tablet. Ozempic (semaglutide) is a GLP-1 receptor agonist given as a once-weekly injection. It slows stomach emptying, helps your body release insulin when blood sugar is high, and reduces appetite. Both may be used for type 2 diabetes and may support weight management. Your healthcare provider will decide which option, if either, fits your care plan.
You take it as one oral tablet once a day, with or without food, at about the same time each day. The usual dose is 10 mg once daily. In some cases, treatment starts at 5 mg once daily and increases to 10 mg depending on your condition, how well you tolerate it, and how you respond. Your provider sets the right dose for you, so do not change it on your own. Store the tablets at room temperature, away from moisture and heat.
The most common side effects are urinary tract infections, genital yeast infections, increased urination, dehydration, and dizziness. Because dapagliflozin has a diuretic effect, it increases urine output, so drinking enough fluid is especially important. These effects can be more noticeable when you start treatment or when you are not drinking enough. Tell your healthcare provider about any side effect or unusual symptom. Your provider can discuss hydration guidance and adjust your care plan if needed.
Yes, you will need regular monitoring. Your healthcare provider will check your blood glucose levels, kidney function, hydration status, and how well the treatment is working. If you are using dapagliflozin to support MASLD or MASH management, your provider may also track liver health with tests such as Liver Function Tests (LFTs) or imaging during routine follow-up. Keep your scheduled appointments, because these checks help your provider balance benefits against risks.
Plan on long-term use unless your provider tells you otherwise. Dapagliflozin is generally used long term for type 2 diabetes, heart failure, or chronic kidney disease. Treatment usually continues as long as you benefit and tolerate it well. Do not stop taking it without talking to your healthcare provider first, even if you feel well. If side effects bother you, report them so your provider can review your options.
Medical disclaimer: LiverDirectory provides educational information and a directory of providers. It does not provide medical advice, diagnosis, or treatment. Always consult a licensed physician regarding any medical condition.
